0001439222-24-000030.txt : 20240214
0001439222-24-000030.hdr.sgml : 20240214
20240214175339
ACCESSION NUMBER: 0001439222-24-000030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gheuens Sarah
CENTRAL INDEX KEY: 0001881190
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 24640978
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080703
4
1
wk-form4_1707951190.xml
FORM 4
X0508
4
2024-02-12
0
0001439222
AGIOS PHARMACEUTICALS, INC.
AGIO
0001881190
Gheuens Sarah
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
1
Common stock
2024-02-12
4
M
0
2162
0
A
34073
D
Common stock
2024-02-14
4
S
0
642
25.14
D
33431
D
Restricted stock units
2024-02-12
4
M
0
2162
0
D
Common stock
2162
0
D
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
2024-02-14